Dr Sarah Sammons outlines a practical decision framework for first-line HER2+ metastatic breast cancer, focusing on choosing THP versus T-DXd + P and then tailoring maintenance to receptor status.
How I think about 1st line HER2+ Metastatic Breast Cancer.
Decision 1: THP versus T-DXd + P
Decision 2: Maintenance based on receptor status
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare